The U.S. Food and Drug Administration today issued draft guidance intended to help drug developers validate new approach methodologies (NAMs) to be used instead of animal testing in drug development, and to bring safe, effective drugs to market sooner based on human-centric data.
FDA News Releases published a clinical update in Research Highlights on 18 Mar 2026. The item focuses on FDA Releases Draft Guidance on Alternatives to Animal Testing in Drug Development. Open the detail page to review the full original feed content.